PRESS DIGEST - Wall Street Journal - March 23
March 23 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
Jan 4 Eli Lilly And Co
* U.S. FDA approves supplemental new drug applications to include landmark data in product labels for synjardy (empagliflozin/metformin hydrochloride), synjardy xr (empagliflozin/metformin hydrochloride extended-release) and glyxambi (empagliflozin/linag
* Eli Lilly and Co - data show empagliflozin reduced risk for cardiovascular death compared with placebo when added to standard of care type 2 diabetes
* Eli Lilly and Co - data have been added to "clinical studies" sections of prescribing information for synjardy, synjardy xr, glyxambi tablets Source text for Eikon: Further company coverage:
* Oil higher as traders see buying opportunity but glut weighs
To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_03232017.pdf If you would like to receive this newsletter via email, please register at: https://forms.thomsonreuters.com/india-morning/ FACTORS TO WATCH 09:30 am: Trade Minister Nirmala Sitharaman at an event in New Delhi 09:45 am: Junior Finance Minister Arjun Ram Meghwal at an event in New Delhi 11:00 am: Budget session of Parliament continues i